コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 d the JNJ-7836735 Johnson & Johnson vaccine (Janssen).
2 f the original product Remicade (infliximab, Janssen).
3 aZeneca), and Ad26.COV2.S (Johnson & Johnson/Janssen).
4 th Insurance Companies, Schering-Plough, and Janssen.
5 ioNTech; VE-D for age 65 years was 52.2% for Janssen, 75.5% for Moderna, and 70.1% for Pfizer-BioNTec
6 NTech; VE-D for age >=65 years was 52.2% for Janssen, 75.5% for Moderna, and 70.1% for Pfizer-BioNTec
7 r 2021, VE-D for age <65 years was 73.0% for Janssen, 81.5% for Moderna, and 84.3% for Pfizer-BioNTec
8 r 2021, VE-D for age <65 years was 73.0% for Janssen, 81.5% for Moderna, and 84.3% for Pfizer-BioNTec
10 2, the Moderna 1273-mRNA, or the single-dose Janssen Ad.26.COV2.S vaccines and partially vaccinated i
11 Ox1 nCoV-19 COVID-19 vaccine (Vaxzevria) and Janssen Ad26.COV2.S COVID-19 vaccine, and it is associat
12 o assess the safety and effectiveness of the Janssen Ad26.COV2.S vaccine among healthcare workers (HC
13 ncertainty in Oxford-AstraZeneca ChAdOx1 and Janssen Ad26.COV2.S VE against any infection, with sligh
14 Moderna mRNA-1273, Pfizer/BioNTech BNT162b2, Janssen Ad26.COV2.S, and Novavax NVX-CoV2373 were examin
15 gical adverse events were reported following Janssen (Ad26.COV2.S) vaccination compared to either Pfi
16 ch-Comirnaty, n=38; Moderna-mRNA-1273, n=23; Janssen-Ad26.COV2.S, n=9; and AstraZeneca-Vaxzevria, n=8
18 nt adenoviral vectored vaccine (Ad26.COV2-S, Janssen), an mRNA vaccine (BNT162b2, Pfizer-BioNTech), o
20 ccinations (n=36: 16 ChAdOx1, 10 Ad26.COV2.S/Janssen, and 10 Tozinameran/Pfizer-BioNTech) without dev
25 h Council, Novartis, Sanofi-Aventis, Pfizer, Janssen, Astellas, NIHR Clinical Research Network, Swiss
26 e of 100 mug, Ad26.COV2.S (Johnson & Johnson-Janssen) at a dose of 5x10(10) virus particles, or BNT16
28 t uveitis treated with infliximab (Remicade; Janssen Biotech, Inc., Titusville, NJ) were identified t
31 nts and 57 healthy control subjects) and the Janssen-Brain Resource Company study (94 patients and 10
32 Crohn's disease who discontinued infliximab (Janssen, Canada, Inc.) and review of the published liter
35 aZeneca; Oxford University) and Ad26.COV2.S (Janssen) coronavirus disease 2019 vaccines and are criti
37 442 healthcare workers who had received the Janssen COVID-19 vaccine between July 11 and 25, 2022.
39 1-3 of the Pfizer, Moderna, AstraZeneca, and Janssen COVID-19 vaccines; outcomes were myocarditis and
48 to as VLA), a half dose of VLA, Ad26.COV2.S (Janssen; hereafter referred to as Ad26) or MenACWY (1:1:
51 Moderna or Pfizer-BioNTech or single dose of Janssen/Johnson & Johnson vaccines) in their EHRs from D
54 BNT162b2 (Pfizer-BioNTech), and Ad26.COV2.S (Janssen/Johnson & Johnson) primary vaccination series an
55 ness of adenovirus vector-based Ad26.COV2.S (Janssen/Johnson & Johnson) to mRNA-based BNT162b2 (Pfize
58 In the US, the Ad26.COV2.S COVID-19 vaccine (Janssen/Johnson & Johnson), which uses a human adenovira
61 discover new antimalarials, a screen of the Janssen Jumpstarter library against Plasmodium falciparu
62 we performed a high-throughput screen of the Janssen Jumpstarter library against the Plasmodium falci
65 d Infectious Diseases, Boehringer Ingelheim, Janssen, Merck, ViiV Healthcare, Roche, and Monogram Bio
67 ch, GlaxoSmithKline, Golub Capital, Insitro, Janssen Neuroscience, Lundbeck, Merck, Meso Scale Discov
68 m 18 randomized clinical trials conducted by Janssen or GlaxoSmithKline for one of nine disorders (N
69 after primary vaccination with Ad26.COV2.S (Janssen) or BNT162b2 (Pfizer/BioNTech) followed by a hom
70 -BioNTech, mRNA-1273 (Moderna), Ad26.COV2.S (Janssen), or ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccin
71 the highest observed differences was trial: Janssen participants had 0.54 log10 copies/mL lower mean
72 Zeneca participants, and 5047/43 788 (11.5%) Janssen participants were identified as having a TIS.
74 logists under a compassionate-use program by Janssen Pharmaceutica, as the manufacturer worked toward
75 tion Global Challenges Research Fund, UKAID, Janssen Pharmaceutica, International AIDS Society, John
76 gy Europe, Amgen, BMS/Celgene International, Janssen Pharmaceutica, Takeda Pharmaceuticals Internatio
82 o assess these models was extracted from the Janssen (PhD's Thesis, Engineering, Civil and Environmen
90 oundation, US National Institutes of Health, Janssen Research & Development, IQVIA, South Korean Mini
104 merican Diabetes Foundation (1-18-ICTS-119); Janssen Research & Development; and the Pershing Square
112 m one site were excluded by the sponsor, the Janssen Research Foundation, because of concern about th
114 rlapping phenotypic features, known as Houge-Janssens syndrome (HJS) types 1, 2, and 3, respectively.
115 se variant E420K, recurrently found in Houge-Janssens syndrome type 1 compromised suppression of lipr
116 Tech), mRNA-1273 (Moderna), or JNJ-78436735 (Janssen) to unvaccinated controls in metropolitan New Yo
117 (REMS) program and reports submitted to the Janssen U.S. Global Medical Safety (US-GMS) database wer
118 ed ratios for GBS, CVT and seizure following Janssen vaccination were >=1.5-fold higher than backgrou
120 n the second week after a single dose of the Janssen vaccine could not be ruled out (RI, 1.75 [CI, 1.
124 and 2, "Moderna" vaccine dose 1 and 2, and "Janssen" vaccine single dose) in the U.S., especially re
126 the first one being the Johnson and Johnson (Janssen) vaccine, or taking 3 or more doses of any of th
127 Harvard University; Cambridge, MA, USA) and Janssen Vaccines & Prevention (Leiden, Netherlands).
129 ccination campaign called UMURINZI offered a Janssen Vaccines & Prevention B.V. 2-dose heterologous E
131 OVAC (grant 115861) and Crucell Holland (now Janssen Vaccines and Prevention B.V.), European Union's
132 Moderna), and Ad26.COV2.S (Johnson & Johnson-Janssen) vaccines at preventing severe acute respiratory
133 Moderna), and Ad26.COV2.S (Johnson & Johnson-Janssen) vaccines in reducing the current risks of Covid